Therefore, the selection of a genetic diagnosis as a clinical trial inclusion criterion (such as “RDH12-associated retinal dystrophy”) would be a way to encompass a larger relevant population and would not hinder the design of a clinical trial if parallel precise phenotypic characterization is used to establish eligibility. Here, RDH12 is linked to Retinal dystrophy.